Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Conference News STS 2020

PE for Surgeons: Be Active Participants in Team-Based Care, Experts Urge

Yael L. Maxwell

February 03, 2020

News Conference News SCAI 2018

ORBITA Continues to Surprise: 85% of Sham Arm Opted for PCI When Trial Ended

L.A. McKeown

April 26, 2018

News Industry News

SurModics Announces First Patient Enrolled in IDE Study of SurVeil™ Drug-Coated Balloon

April 06, 2016

News Industry News

SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil™ Drug-Coated Balloon

October 06, 2015

News Daily News

LEVANT 2: Un BRF Supera a la Angioplastia con Balón Estándar al cabo de 1 Año en el Manejo de la Enfermedad Femoropoplítea

Yael L. Maxwell

June 26, 2015

News Daily News

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

Yael L. Maxwell

June 26, 2015

News Daily News

LEVANT 2：DCB 治疗股腘动脉疾病的 1 年随访结果优于标准球囊成形术

Yael L. Maxwell

June 26, 2015

Presentation

Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Presenter: Kenneth Rosenfield

June 25, 2015

News Industry News

The New England Journal of Medicine publishes LEVANT 2 results for the Lutonix® Drug Coated Balloon, showing superior efficacy compared to standard PTA

June 25, 2015

Presentation TCT 2013

LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

Presenter: Kenneth Rosenfield

October 30, 2013

News Conference News TCT 2013

LEVANT 2, RIBS Show Promise for Paclitaxel-Coated Balloons in PAD and CAD

October 30, 2013

Advertisement

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

PE for Surgeons: Be Active Participants in Team-Based Care, Experts Urge

ORBITA Continues to Surprise: 85% of Sham Arm Opted for PCI When Trial Ended

SurModics Announces First Patient Enrolled in IDE Study of SurVeil™ Drug-Coated Balloon

SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil™ Drug-Coated Balloon

LEVANT 2: Un BRF Supera a la Angioplastia con Balón Estándar al cabo de 1 Año en el Manejo de la Enfermedad Femoropoplítea

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

LEVANT 2：DCB 治疗股腘动脉疾病的 1 年随访结果优于标准球囊成形术

Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

The New England Journal of Medicine publishes LEVANT 2 results for the Lutonix® Drug Coated Balloon, showing superior efficacy compared to standard PTA

LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

LEVANT 2, RIBS Show Promise for Paclitaxel-Coated Balloons in PAD and CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content